NASDAQ: RLYBRallybio Corp Stock
$1.58-0.16 (-9.2%)
Updated Apr 24, 2024
RLYB Price
$1.58
Fair Value Price
$0.60
Market Cap
$59.74M
52 Week Low
$1.23
52 Week High
$9.14
P/E
-0.86x
P/B
0.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$74.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$60M
Beta
1.22
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RLYB Overview
Rallybio Corporation is a clinical-stage biotechnology company offering programs for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company is also focused on developing therapies that address diseases of complement dysregulation, including Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, and ophthalmic disorders. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, CT.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RLYB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RLYB ($1.58) is overvalued by 165.15% relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RLYB ($1.58) is not significantly undervalued (165.15%) relative to our estimate of its Fair Value price of $0.60 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RLYB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RLYB due diligence checks available for Premium users.
Be the first to know about important RLYB news, forecast changes, insider trades & much more!
RLYB News
Valuation
RLYB fair value
Fair Value of RLYB stock based on Discounted Cash Flow (DCF)
Price
$1.58
Fair Value
$0.60
Overvalued by
165.15%
RLYB ($1.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RLYB ($1.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RLYB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RLYB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.86x
Industry
15.69x
Market
41.27x
RLYB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.56x
Industry
5.86x
RLYB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RLYB's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.2M
Profit Margin
0%
RLYB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$115.6M
Liabilities
$9.4M
Debt to equity
0.09
RLYB's short-term assets ($114.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLYB's short-term assets ($114.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLYB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.6M
Investing
$16.9M
Financing
$72.0k
RLYB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RLYB vs Biotech Stocks
Rallybio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.